Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 2, 2026

Nobody Could Answer the CFO’s Question on the ROI from AI Adoption; TechWish Built a Platform That Can

View original at finance.yahoo.com
Nobody Could Answer the CFO’s Question on the ROI from AI Adoption; TechWish Built a Platform That Can Platform validated at a major Fortune 500 energy company, establishing an estimated 20× productivity ROI and 44% increase in active Copilot utilization within 90 days STERLING, Va., April 02, 2026 (GLOBE NEWSWIRE) --…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • More than two-thirds of organizations continue to rely on manual or projected ROI tracking, even for AI systems already in production

    60% confidence
  • Native reporting dashboards inherent in AI tools can show baseline usage activity but lack contextual view required to answer leadership questions about genuine AI integration, enablement program effectiveness, and productivity outcomes

    60% confidence
  • More than two-thirds of organizations continue to rely on manual or projected ROI tracking for AI systems in production

    60% confidence
  • Only 39% of organizations report measurable business impact from generative AI, with two-thirds still characterizing their deployments as experimental or in piloting stages

    60% confidence
  • Evidence-based ROI reporting is becoming a board-level imperative, not just a reporting function

    60% confidence
  • Platform validated at a major Fortune 500 energy company, establishing an estimated 20× productivity ROI and 44% increase in active Copilot utilization within 90 days

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com